Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells

Cancer Research

Volumn 59, Issue 22, 1999, Pages 5692-5694

  O'Gorman, David B ^a   Costello, Michael ^a   Weiss, Jocelyn ^a   Firth, Sue M ^a   Scott, Carolyn D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR;

ARTICLE; CARCINOGENICITY; CELL GROWTH; CHORIOCARCINOMA; DNA TRANSFECTION; GROWTH REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

ANIMALS; ANTISENSE ELEMENTS (GENETICS); CELL DIVISION; CHORIOCARCINOMA; DOWN-REGULATION; FEMALE; HUMANS; MICE; MICE, NUDE; RECEPTOR, IGF TYPE 2; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033571113     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Nissley, P., Kiess, W., and Sklar, M. M. The insulin-like growth factor-II/mannose 6-phosphate receptor. In: D. Le Roith (ed.), Insulin-Like Growth Factors: Molecular and Cellular Aspects, pp. 111-150. Boca Raton, FL: CRC Press, 1991.
2. Polychronakos, C., Guyda, H. J., Janthly, U., and Posner, B. I. Effects of mannose-6-phosphate on receptor-mediated endocytosis of insulin-like growth factor-II. Endocrinology, 127: 1861-1866, 1990.
3. Ludwig, T., Eggenschwiler, J., Fisher, P., D'Ercole, A. J., Davenport, M. L., and Efstratiadis, A. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev. Biol., 177: 517-535, 1996.
4. Ouyang, H., Shiwaku, H. O., Hagiwara, H., Miura, K., Abe, T., Kato, Y., Ohtani, H., Shiiba, K., Souza, R. F., Meltzer, S. J., and Horii, A. The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum. Cancer Res., 57: 1851-1854, 1997.
5. Wang, S., Souza, R. F., Kong, D., Yin, J., Smolinski, K. N., Zou, T. T., Frank, T., Young, J., Flanders, K. C., Sugimura, H., Abraham, J. M., and Meltzer, S. J. Deficient transforming growth factor-β1 activation and excessive insulin-like growth factor II (IGFII) expression in IGFII receptor-mutant tumors. Cancer Res., 57: 2543-2546, 1997.
6. Costello, M., Baxter, R. C., and Scott, C. D. Regulation of soluble insulin-like growth factor II/mannose 6-phosphate receptor in human serum: measurement by enzyme-linked immunosorbent assay. J. Clin. Endocrinol. Metab., 84: 611-617, 1999.
7. Cesarone, C. F., Bolognesi, C., and Santi, L. Improved microfluorometric DNA determination in biological material using 33258 Hoechst. Anal. Biochem., 700: 188-197, 1979.
8. Giudice, L. C. Growth factors and growth modulators in human uterine endometrium: their potential relevance to reproductive medicine. Fertil. Steril., 61: 1-17, 1994.
9. Graham, C. H., and Lala, P. K. Mechanisms of placental invasion of the uterus and their control. Biochem. Cell Biol., 70: 867-874, 1992.
10. Ohlsson, R., Holmgren, L., Glaser, A., Szpecht, A., and Pfeifer-Ohlsson, S. Insulin-like growth factor 2 and short-range stimulatory loops in control of human placental growth. EMBO J., 8: 1993-1999, 1989.
11. Ritvos, O., Rutanen, E. M., Pekonen, F., Jalkanen, J., Suikkari, A. M., and Ranta, T. Characterization of functional type I insulin-like growth factor receptors from human choriocarcinoma cells. Endocrinology, 122: 395-401, 1988.
12. MacDonald, R. G. Mannose-6-phosphate enhances cross-linking efficiency between insulin-like growth factor-II (IGF-II) and IGF-II/mannose-6-phosphale receptors in membranes. Endocrinology, 128: 413-421, 1991.
13. Ritvos, O., Ranta, T., Jalkanen, J., Suikkari, A. M., Voutilainen, R., Bohn, H., and Rutanen, E. M. Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells. Endocrinology, 122: 2150-2157, 1988.
14. Fagin, J. A., Pixley, S., Slanina, S., Ong, J., and Melmed, S. Insulin-like growth factor I gene expression in GH3 rat pituitary cells: messenger ribonucleic acid content, immunocytochemistry, and secretion. Endocrinology, 120: 2037-2043, 1987.
15. Daughaday, W. H. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology, 127: 1-4, 1990.
16. Dennis, P. A., and Rifkin, D. B. Cellular activation of latent transforming growth factor β requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc. Natl. Acad. Sci. USA, 88: 580-584, 1991.
17. Sohar, I., Sleat, D., Liu, C. G., Ludwig, T., and Lobel, P. Mouse mutants lacking the cation-independent mannose 6-phosphate/insulin-like growth factor II receptor are impaired in lysosomal enzyme transport: comparison of cation-independent and cation-dependent mannose 6-phosphate receptor-deficient mice. Biochem. J., 330: 903-908, 1998.
18. Nykjaer, A., Christensen, E. I., Vorum, H., Hager, H., Petersen, C. M., Roigaard, H., Min, H. Y., Vilhardt, F., Moller, L. B., Kornfeld, S., and Gliemann, J. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J. Cell Biol., 141: 815-828, 1998.
19. Tryggvason, K., Hoyhtya, M., and Salo, T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim. Biophys. Acta, 907: 191-217, 1987.